Royalty Pharma PLC
NASDAQ:RPRX

  • LAST PRICE
    27.0200
  • TODAY'S CHANGE (%)
    0.1800 (0.6706%)
  • Bid / Lots
    26.5000/ 2
  • Ask / Lots
    27.4100/ 1
  • Open / Previous Close
    26.7500 / 26.8400
  • Day Range
    26.4700
    27.0400
  • 52 Week Range
    25.9200
    34.6500
  • Volume
    2,156,230

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
RPRX
Royalty Pharma PLC
16.4B
15.2x
+1.83%
AMRX
Amneal Pharmaceuticals Inc
2.1B
-11.8x
---
CTLT
Catalent Inc
9.7B
-8.5x
---
JAZZ
Jazz Pharmaceuticals PLC
6.6B
21.6x
-3.53%
MCKPF
Mallinckrodt PLC
1.6M
0.0x
---
PBH
Prestige Consumer Healthcare Inc
3.2B
15.4x
---
As of 2024-06-04

Company Information

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Contact Information

Headquarters
110 East 59th StreetNEW YORK, NY, United States 10022
Phone
212-883-0200
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Pablo Legorreta
Vice Chairman, Executive Vice President
Christopher Hite
Chief Financial Officer, Executive Vice President
Terrance Coyne
Executive Vice President - Investments and Chief Legal Officer
George Lloyd
Executive Vice President - Research and Investments
Marshall Urist

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$16.4B
Revenue (TTM)
$2.2B
Shares Outstanding
597.4M
Dividend Yield
3.11%
Annual Dividend Rate
0.8400 USD
Ex-Dividend Date
05-16-24
Pay Date
06-14-24
Beta
0.47
EPS
$1.78
Book Value
$14.61
P/E Ratio
15.2x
Price/Sales (TTM)
7.3
Price/Cash Flow (TTM)
13.7x
Operating Margin
41.96%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.